Bio Innovation Conference Maryland


Oct 4 – Oct 5

Our MaxCyte team was at the Maryland Life Sciences Bio Innovation Conference where we had the opportunity to connect with top life sciences professionals in the region with leading global brands, venture capitalists and promising startups. Created by life sciences professionals for life sciences professionals, this forum offered an exciting and unique opportunity to reach industry leaders and decision makers across the industry and demonstrate to colleagues and clients how your products or services can lead the way to a healthier tomorrow.

Sponsored Events

Monday, October 3rd at 10:00 am

Session 1: Expanding the Boundaries of Cell & Gene Therapy (Sponsored by MaxCyte)


Since 2016 there has been a renaissance in the cell and gene therapy field, building an impressive pipeline of 24 approved therapies by the FDA. Requiring decades of innovation efforts, the list of licensed products includes autologous T cell immunotherapies, AAV vector-based gene therapies, and allogeneic cell therapies. These therapies treat diverse clinical indications and tissue targets, including cancer, neuromuscular disease, neurodegenerative disease, and retinal dystrophy. This informative session features executive-level speakers from three Maryland-based biotechnology companies whose core mission is to expand boundaries to create a new generation of therapies that will enhance patient outcomes through cell engineering, RNA engineering and AAV gene therapy.


Lesley Eschinger

Director of Market Development, MaxCyte


Cenk Sumen

Chief Scientific Officer, MaxCyte

Dr. Milos Miljkovic

Chief Medical Officer, Cartesian Therapeutics

Craig Malzahn

Senior Vice President, Technical Operations, REGENXBIO

Monday, October 3rd at 11:00 am

Session 2: Factors Impacting Patient Access to Cell and Gene Therapies (Sponsored by MaxCyte)


Patient/doctor relationship: challenges they go through in terms of access, getting into clinical trials, rare diseases/new diseases, how to get patients access to life saving therapies/what barriers they overcome.


Dr. Cartier Esham

Chief Scientific Officer, Biotechnology Industry Organization


Colin Werth

Parent Project Muscular Dystrophy

Nina Hunter

Vice President of Regulatory and Science Policy, REGENXBIO

Clinician: Johns Hopkins (Emily English); UMMC – Dr. Aaron Rappaport or Dr. Nancy Hardy

Lucy Culp

Leukemia/Lymphoma Society

Mark Trusheim

Strategic Director, NEWDIGS, Sloan School of Management MIT